A Phase 3 interventional study of Troriluzole and Placebo in Obsessive-Compulsive Disorder, sponsored by Biohaven Pharmaceuticals, Inc.. Completed at 73 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Biohaven Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
635 studies on the registry are indexed under Obsessive-Compulsive Disorder; 166 are open to participants now.
This study's enrollment of 456 is above the median of 45 across 520 interventional studies indexed under Obsessive-Compulsive Disorder.
Browse Obsessive-Compulsive Disorder studies →Biohaven Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 6 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Troriluzole - 2 100mg capsules once daily for the first two weeks. Troriluzole - 2 140mg capsules once daily from week two through week ten.
Drug: Troriluzole
Placebo - 2 100mg capsules once daily for the first two weeks. Placebo - 2 140mg capsules once daily from week two through week ten.
Drug: Placebo
Troriluzole - 2 100mg capsules QD for the first two weeks.
Matching placebo - 2 140mg capsules QD from week two through week ten.
The total score on the Yale-Brown Obsessive Compulsive Scale (YBOCS)
Improvement is measured by a lower total score
Time frame: Change in total score from baseline, assessed at screening, baseline, week 4, 8 &10
Frequency of SAEs and AEs leading to discontinuation
Percent difference between troriluzole vs placebo treatment emergent adverse events.
Time frame: From Screening through study completion, up to 10 weeks
Improvement in functional disability as assessed by the change in Sheehan Disability Scale (SDS)
Change is measured as "mild" or "moderate" on the SDS
Time frame: From baseline through study completion (up to 10 weeks)
Improvement in global functioning responses assessed on the CGI-I scale.
Change is measured as "much improved" or "very much improved" on the CGII scale
Time frame: From baseline through study completion (up to 10 weeks)
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Troriluzole
Obsessive-Compulsive Disorder →
Biohaven Pharmaceuticals, Inc.